SLC5A2 and type 2 diabetes mellitus: Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed as antihyperglycemic agents for type 2 diabetes, have gained attention for their broad cardioprotective and renoprotective benefits [13, 14].